[go: up one dir, main page]

AU3375199A - Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders - Google Patents

Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders

Info

Publication number
AU3375199A
AU3375199A AU33751/99A AU3375199A AU3375199A AU 3375199 A AU3375199 A AU 3375199A AU 33751/99 A AU33751/99 A AU 33751/99A AU 3375199 A AU3375199 A AU 3375199A AU 3375199 A AU3375199 A AU 3375199A
Authority
AU
Australia
Prior art keywords
antagonists
specific gene
growth arrest
treat insulin
arrest specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33751/99A
Inventor
Timothy Andrew Stewart
Elizabeth Tomlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU3375199A publication Critical patent/AU3375199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33751/99A 1998-04-01 1999-03-31 Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders Abandoned AU3375199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8027998P 1998-04-01 1998-04-01
US60080279 1998-04-01
PCT/US1999/007093 WO1999049894A1 (en) 1998-04-01 1999-03-31 Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders

Publications (1)

Publication Number Publication Date
AU3375199A true AU3375199A (en) 1999-10-18

Family

ID=22156373

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33751/99A Abandoned AU3375199A (en) 1998-04-01 1999-03-31 Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders

Country Status (2)

Country Link
AU (1) AU3375199A (en)
WO (1) WO1999049894A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1199081A1 (en) * 2000-10-20 2002-04-24 Vlaams Interuniversitair Instituut voor Biotechnologie Use of inhibition of a growth arrest-specific gene (gas6) function or of a gas6 receptor for preventing and treating a thromboembolic disease
WO2001078778A1 (en) * 2000-04-13 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE
WO2003029485A2 (en) * 2001-10-02 2003-04-10 Azign Bioscience A/S Specific differential display arrays
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214629C (en) * 1995-03-10 2001-07-10 Genentech, Inc. Receptor activation by gas6
WO1997026005A1 (en) * 1996-01-16 1997-07-24 Genentech, Inc. Igf-i in combination with hypoglycemics for treatment of diabetes

Also Published As

Publication number Publication date
WO1999049894A1 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IL138129A (en) Composition for therapy of estrogen-associated disorders
AU2541899A (en) Desiccation electrode
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2325999A (en) Methods of neuroendocrine regulation of affective disorders
AU2058697A (en) Treatment of sleep disorders
AU5042000A (en) Methods of treating proliferative disorders
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
HUP0102436A3 (en) Use of reboxetin for preparation of medicament for nervous disorders
AU3375199A (en) Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
AU4704797A (en) Use of benzopyranols to treat neurological disorders
AU3047299A (en) Methods of delivering glp-1
AU4415797A (en) New pde iv inhibitors: "bis-compounds"
AU1133901A (en) Method of treating metabolic disorders
AU3386199A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
AU2001232243A1 (en) Nerve growth factor activity potentiating agents
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU7516098A (en) Immunomodulating, bile-derivable compositions for the treatment of viral disorders
EP1646395B8 (en) Methods and compositions for regulating lymphocyte activity
AU3765899A (en) Serotonergic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase